Advertisement

Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis

  • Tomoo Sato
  • Yoshihisa Yamano
  • Utano Tomaru
  • Yukiko Shimizu
  • Hitoshi Ando
  • Takahiro Okazaki
  • Hiroko Nagafuchi
  • Jun Shimizu
  • Shoichi Ozaki
  • Teruomi Miyazawa
  • Kazuo Yudoh
  • Hiroshi Oka
  • Noboru Suzuki
Original Article

Abstract

Objectives

We aimed to identify a serum biomarker for evaluating the disease activity of relapsing polychondritis (RP).

Methods

We measured and compared serum levels of 28 biomarkers potentially associated with this disease, including soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), high-sensitivity C-reactive protein (hs-CRP), and cartilage oligomeric matrix protein (COMP), in 15 RP patients and 16 healthy donors (HDs). We divided the 15 RP patients into active RP (n = 8) and inactive RP (n = 7) groups, depending on the extent of the disease, and compared candidate markers between groups. The localization of membrane-bound TREM-1 in the affected tissue was examined by immunohistochemistry.

Results

Serum levels of sTREM-1, interferon-γ, chemokine (C–C motif) ligand 4, vascular endothelial growth factor, and matrix metalloproteinases-3 were significantly higher in RP patients than HDs. Among these markers, sTREM-1 had the highest sensitivity and specificity (86.7 and 86.7 %, respectively). Furthermore, the serum level of sTREM-1 was significantly higher in active RP patients than inactive RP patients (p = 0.0403), but this was not true for hs-CRP or COMP. TREM-1 was expressed on endothelial cells in RP lesions.

Conclusions

The serum level of sTREM-1 may be a useful marker of disease activity in RP.

Keywords

Relapsing polychondritis Serum marker Soluble triggering receptor expressed on myeloid cells-1 

Notes

Acknowledgments

We would like to thank Katsunori Takahashi, Yasuo Kunitomo, Yuji Sato, Mikako Koike, and Yumiko Hasegawa for their excellent technical help. This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare, Japan.

Conflict of interest

None.

References

  1. 1.
    Jaksch-Wartenhorst R. Polychondropathia. Wien Arch Inn Med. 1923;6:100.Google Scholar
  2. 2.
    Pearson CM, Kline HM, Newcomer VD. Relapsing polychondritis. N Engl J Med. 1960;263:51–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Lahmer T, Treiber M, von Werder A, Foerger F, Knopf A, Heemann U, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev. 2010;9:540–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Kemta Lekpa F, Kraus VB, Chevalier X. Biologics in relapsing polychondritis: a literature review. Semin Arthritis Rheum. 2012;41:712–9.Google Scholar
  5. 5.
    Rapini RP, Warner NB. Relapsing polychondritis. Clin Dermatol. 2006;24:482–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Foidart JM, Abe S, Martin GR, Zizic TM, Barnett EV, Lawley TJ, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299:1203–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kempta Lekpa F, Piette JC, Bastuji-Garin S, Kraus VB, Stabler TV, Poole AR, et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. Clin Exp Rheumatol. 2010;28:553–5.Google Scholar
  8. 8.
    Michet CJ. Diagnostic evaluation of relapsing polychondritis. http://www.uptodate.com/contents/diagnostic-evaluation-of-relapsing-polychondritis.
  9. 9.
    Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthr Rheum. 1990;33:1493–500.CrossRefGoogle Scholar
  10. 10.
    Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol. 2004;16:56–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Gomez-Pina V, Soares-Schanoski A, Rodriguez-Rojas A, Del Fresno C, Garcia F, Vallejo-Cremades MT, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol. 2007;179:4065–73.PubMedGoogle Scholar
  12. 12.
    Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res. 2004;2:181–7.PubMedCrossRefGoogle Scholar
  13. 13.
    McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55:193–215.CrossRefGoogle Scholar
  14. 14.
    Damiani JM, Levine HL. Relapsing polychondritis—report of ten cases. Laryngoscope. 1979;89:929–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991–5.PubMedGoogle Scholar
  16. 16.
    Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol. 2008;84:145–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004;141:9–15.PubMedGoogle Scholar
  18. 18.
    Gibot S, Cravoisy A, Kolopp-Sarda MN, Bene MC, Faure G, Bollaert PE, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005;33:792–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, et al. Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol. 2005;142:62–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T, Koutoukas P, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol. 2006;12:3416–9.PubMedGoogle Scholar
  21. 21.
    Kuai J, Gregory B, Hill A, Pittman DD, Feldman JL, Brown T, et al. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford). 2009;48:1352–8.CrossRefGoogle Scholar
  22. 22.
    Daikeler T, Regenass S, Tyndall A, Gencay MM, Roth M, Christ-Crain M, et al. Increased serum levels of soluble triggering receptor expressed on myeloid cells-1 in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2008;67:723–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Michet CJ. Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am. 1990;16:441–4.PubMedGoogle Scholar
  24. 24.
    Zeuner M, Straub RH, Rauh G, Albert ED, Scholmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96–101.PubMedGoogle Scholar
  25. 25.
    Bleharski JR, Kiessler V, Buonsanti C, Sieling PA, Stenger S, Colonna M, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol. 2003;170:3812–8.PubMedGoogle Scholar
  26. 26.
    Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthr Rheum. 2009;60:1615–23.CrossRefGoogle Scholar
  28. 28.
    Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthr Rheum. 2000;43:852–8.CrossRefGoogle Scholar

Copyright information

© Japan College of Rheumatology 2013

Authors and Affiliations

  • Tomoo Sato
    • 1
  • Yoshihisa Yamano
    • 1
  • Utano Tomaru
    • 2
  • Yukiko Shimizu
    • 1
  • Hitoshi Ando
    • 1
  • Takahiro Okazaki
    • 3
  • Hiroko Nagafuchi
    • 3
  • Jun Shimizu
    • 4
  • Shoichi Ozaki
    • 3
  • Teruomi Miyazawa
    • 5
  • Kazuo Yudoh
    • 1
  • Hiroshi Oka
    • 6
  • Noboru Suzuki
    • 4
  1. 1.Institute of Medical ScienceSt. Marianna University School of MedicineKawasakiJapan
  2. 2.Department of PathologyHokkaido University Graduate School of MedicineSapporoJapan
  3. 3.Division of Rheumatology and Allergy, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  4. 4.Departments of Immunology and MedicineSt. Marianna University School of MedicineKawasakiJapan
  5. 5.Division of Respiratory and Infectious Diseases, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  6. 6.Rheumatic Disease CenterTokyo Medical University Hachioji Medical CenterHachiojiJapan

Personalised recommendations